There is a possibility of application of DDR inhibitors across additional PTCL subgroups, since the features of MYC activity, genomic instability, and loss of TP53/CDKN2A/B, found in PTCL‐GATA3, are linked with increased replication stress and DDR activation in other cancers (Kwok et al, 2016; Gadhikar et al, 2018; Young et al, 2019). Here, CDKN2A is linked to cancer.